drugset / Trial / NCT00045591
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Phase 2
Terminated
39 enrolled
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. It is not yet known which regimen of celecoxib is more effective in treating breast cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of celecoxib in treating women who have metastatic or recurrent breast cancer
Timeline
- Start
- 2003-02
- Primary completion
- 2005-08
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 100 mg | Oral |
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |